As of 2025-06-27, the EV/EBITDA ratio of Adamas Pharmaceuticals Inc (ADMS) is -10.98. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ADMS's latest enterprise value is 424.04 mil USD. ADMS's TTM EBITDA according to its financial statements is -38.62 mil USD. Dividing these 2 quantities gives us the above ADMS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.9x - 10.7x | 9.6x |
| Forward P/E multiples | 11.2x - 19.0x | 14.9x |
| Fair Price | (10.61) - (10.20) | (11.54) |
| Upside | -229.1% - -224.1% | -240.4% |
| Date | EV/EBITDA |